Onercept
From PeptidePlaza, the free peptide reference · Entry #1145 · Recovery · Sources fetched 2026-09-11 · Editorial standards
Onercept is a recovery research peptide. Onercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor that has been investigated for its role in inflammatory conditions.
Onercept is a protein-based therapeutic agent classified as a TNF-alpha inhibitor. It functions by binding to and inhibiting the activity of tumor necrosis factor-alpha, a cytokine involved in systemic inflammation. The compound has been studied in clinical trials for its potential in treating inflammatory conditions, including psoriatic arthritis and Crohn's disease. Onercept has reached Phase 3 clinical development, indicating advanced investigation into its therapeutic applications. Research has explored its pharmacokinetics in healthy subjects and its efficacy in conditions such as moderate-to-severe Crohn's disease.
1 Mechanism of action
TNF-alpha inhibitor (inhibitor)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Indicated / studied for
- Psoriatic Arthritis
3 Chemical and physical properties
| Purity (typical) | Not independently verified |
|---|---|
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
4 Research studies (8)
- Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis
Current medical research and opinion (2010) · Review - New biologic therapeutics for ulcerative colitis and Crohn's disease
Expert opinion on biological therapy (2014) · Review - Population pharmacokinetics of onercept in healthy subjects
Clinical pharmacokinetics (2005) · RCT - Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006) · RCT - Onercept. Serono
Current opinion in investigational drugs (London, England : 2000) (2003) · Review - Biologic therapy of inflammatory bowel disease
Gastroenterology (2002) · Review - Strategies for targeting tumour necrosis factor in IBD
Best practice & research. Clinical gastroenterology (2003) · Review - Anti-TNF therapy in Crohn's disease
Novartis Foundation symposium (2004) · Review
5 Safety and risk profile
5.1 Regulatory status
Onercept is currently classified as Phase 3 clinical trials. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
6 Frequently asked questions
- What is onercept?
- Onercept is a tumor necrosis factor-alpha (TNF-alpha) inhibitor, a type of protein-based therapeutic agent. It is designed to modulate the immune response by targeting a key inflammatory cytokine.
- How does onercept work?
- Onercept works by inhibiting tumor necrosis factor-alpha (TNF-alpha). It binds to TNF-alpha, preventing it from interacting with its receptors and thereby reducing its pro-inflammatory effects in the body.
- What is onercept studied for?
- Onercept has been studied for its potential therapeutic use in inflammatory conditions. Clinical trials have investigated its efficacy in treating psoriatic arthritis and moderate-to-severe Crohn's disease.
- What is the regulatory status of onercept?
- Onercept has advanced to Phase 3 clinical development. This stage involves large-scale trials to confirm its effectiveness, monitor side effects, and compare it to standard treatments.
7 References
- Onercept — molecule record ChEMBL. View source
- Onercept — published literature (30 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Onercept.
Also recovery
Lenercept is a TNF-alpha inhibitor that has been investigated for its anti-inflammatory properties.
Also recovery
Bradykinin is an endogenous human peptide involved in various physiological processes, including blood coagulation and inflammation.
Also recovery
A 28-amino acid thymic peptide that modulates T-cell function and cytokine balance. Studied clinically for chronic hepatitis B, sepsis, and vaccine response augmentation for over 30 years.
Also recovery
A single amino acid substitution turns GLP-2 from a 7-minute hormone into a drug that regrows intestinal villi. The only approved peptide that makes the gut physically bigger.
Also recovery
A synthetic ghrelin-mimetic hexapeptide that potently stimulates GH release through the ghrelin receptor. One of the first growth hormone secretagogues developed, with over 25 years of research history.
Also recovery
A 15-amino acid cytoprotective peptide derived from human gastric juice. Widely researched for wound healing, tendon repair, and GI protection across hundreds of animal studies.